Patents by Inventor Hsieng Sen Lu
Hsieng Sen Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210179722Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: December 3, 2020Publication date: June 17, 2021Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Publication number: 20210179723Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: December 3, 2020Publication date: June 17, 2021Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, Jr., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Publication number: 20210040189Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.Type: ApplicationFiled: September 9, 2020Publication date: February 11, 2021Applicant: AMGEN INC.Inventors: William Gleason RICHARDS, Hsieng Sen LU, Hua Zhu KE, Chaoyang LI, Frederick W. JACOBSEN
-
Patent number: 10800839Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.Type: GrantFiled: December 13, 2017Date of Patent: October 13, 2020Assignee: AMGEN INC.Inventors: William Gleason Richards, Hsieng Sen Lu, Hua Zhu Ke, Chaoyang Li, Frederick W. Jacobsen
-
Publication number: 20180142029Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: November 28, 2017Publication date: May 24, 2018Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Publication number: 20180111985Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.Type: ApplicationFiled: December 13, 2017Publication date: April 26, 2018Applicant: Amgen Inc.Inventors: William Gleason RICHARDS, Hsieng Sen LU, Hua Zhu KE, Chaoyang LI, Frederick W. JACOBSEN
-
Patent number: 9879072Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.Type: GrantFiled: October 27, 2011Date of Patent: January 30, 2018Assignee: AMGEN INC.Inventors: William Gleason Richards, Hsieng Sen Lu, Hua Zhu Ke, Chaoyang Li, Frederick W. Jacobsen
-
Patent number: 9862771Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: GrantFiled: June 26, 2015Date of Patent: January 9, 2018Assignee: AMGEN INC.Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
-
Patent number: 9353174Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: February 20, 2014Date of Patent: May 31, 2016Assignee: AMGEN INC.Inventors: Christopher J. Paszty, Hsieng Sen Lu
-
Publication number: 20150376286Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: June 26, 2015Publication date: December 31, 2015Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Publication number: 20150322144Abstract: There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them.Type: ApplicationFiled: March 19, 2015Publication date: November 12, 2015Inventors: Huiquan Han, Taruna Arora, Qing Chen, Hsieng Sen Lu, Xiaolan Zhou
-
Patent number: 9102731Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: GrantFiled: December 18, 2009Date of Patent: August 11, 2015Assignee: AMGEN INC.Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
-
Patent number: 8999343Abstract: Myostatin antagonists, including myostatin binding antibodies, are disclosed. Also disclosed are nucleic acids encoding and cells including myostatin antagonists; methods of production; and methods of use.Type: GrantFiled: August 15, 2011Date of Patent: April 7, 2015Assignee: Amgen Inc.Inventors: Huiquan Han, Taruna Arora, Qing Chen, Hsieng Sen Lu, Xiaolan Zhou
-
Publication number: 20140248666Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: ApplicationFiled: February 20, 2014Publication date: September 4, 2014Applicant: Amgen Inc.Inventors: Christopher J. Paszty, Hsieng Sen Lu
-
Patent number: 8715663Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: April 28, 2011Date of Patent: May 6, 2014Assignee: Amgen Inc.Inventors: Christopher J. Paszty, Hsieng Sen Lu
-
Publication number: 20130209489Abstract: There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and position 50 to 60.Type: ApplicationFiled: August 15, 2011Publication date: August 15, 2013Inventors: Huiquan Han, Taruna Arora, Qing Chen, Hsieng Sen Lu, Xiaolan Zhou
-
Publication number: 20130209475Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.Type: ApplicationFiled: October 27, 2011Publication date: August 15, 2013Inventors: William Gleason Richards, Hsieng Sen Lu, Hua Zhu Ke, Chaoyang Li, Frederick W. Jacobsen
-
Publication number: 20130071410Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related, disorders including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: September 12, 2012Publication date: March 21, 2013Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, JR., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
-
Publication number: 20120087912Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.Type: ApplicationFiled: December 12, 2011Publication date: April 12, 2012Applicant: AMGEN INC.Inventors: Ji Li, Wenyan Shen, Hsieng Sen Lu, William Gleason Richards
-
Patent number: 8101184Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.Type: GrantFiled: October 21, 2009Date of Patent: January 24, 2012Assignee: Amgen Inc.Inventors: Ji Li, Wenyan Shen, Hsieng Sen Lu, William Gleason Richards